指南与共识肝病消化道肿瘤与早癌

2025 AASLD 慢性乙型肝炎管理指南技术性系统评价

Technical systematic review supporting the 2025 AASLD Practice Guideline on management of chronic hepatitis B.
指南 / 共识 · Hepatology · 2025-11-04

该技术性系统评价围绕 4 个 PICO 问题支持 2025 AASLD 慢性乙型肝炎管理指南制定。结果显示:高危人群抗病毒预防水平传播证据有限;免疫耐受期治疗获益不确定;HBeAg 阴性且 HBV DNA 检测不到者停药增加 HBsAg 清除但病毒学复发风险高;合并 HCV、HDV 或 HIV 感染者 HCC 年发病率高于筛查成本效益阈值。

要点

  • 高危人群抗病毒治疗可能降低水平传播风险,但证据确定性低。
  • HBeAg 阴性且 HBV DNA 检测不到者停药增加 HBsAg 清除但复发风险高。
  • 合并 HCV、HDV 或 HIV 者 HCC 年发病率高于筛查成本效益阈值。

核心结论

  • 证据确定性虽低,结果支持在高危水平传播场景或免疫耐受期治疗中共同决策,对无 HBsAg 清除的病毒学抑制者停药需谨慎,并对合并感染或肝硬化者定制 HCC 监测。

研究设计与样本

  • 技术性系统评价,按 PRISMA 指南报告,围绕 4 个 PICO 问题评估结局以支持 2025 AASLD 慢性乙型肝炎管理指南制定。

主要发现

  • PICO 1:有限证据提示抗病毒治疗可能降低水平传播风险,但确定性低。
  • PICO 2:免疫耐受期治疗获益不确定,因异质性和偏倚确定性极低。
  • PICO 3:HBeAg 阴性且 HBV DNA 检测不到者停药增加 HBsAg 清除率(OR:12.65,95%CI:1.58-101.51),但病毒学复发风险中等(OR:47.17,95%CI:2.79-797.35)且可致临床发作。
  • PICO 4:合并 HCV、HBV 或 HIV 者 HCC 年发病率高于筛查成本效益阈值,提示定期肝癌筛查可能有益。

关键数值与推荐

  • PICO 3 停药 vs 继续核苷(酸)类似物:HBsAg 清除 OR 12.65(95%CI 1.58-101.51),病毒学复发 OR 47.17(95%CI 2.79-797.35)。
  • PICO 4:合并 HCV、HBV 或 HIV 者 HCC 年发病率高于筛查成本效益阈值。

临床怎么用

  • 高危水平传播场景或免疫耐受期治疗应共同决策。
  • 无 HBsAg 清除的病毒学抑制者停药需谨慎。
  • 合并 HCV、HDV 或 HIV 或肝硬化者应定制 HCC 监测。

局限性

  • PICO 1 证据有限且确定性低。
  • PICO 2 因异质性和偏倚确定性极低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: With rapid changes in the management landscape of chronic hepatitis B (CHB), this technical systematic review addresses 4 critical Population, Intervention, Comparator, Outcome (PICO) questions to provide guidance to the formulation of recommendations to the 2025 AASLD practice guideline for management of CHB. APPROACH: The review was reported in accordance with PRISMA guidelines. Outcomes were evaluated across 4 key PICOs: (1) antiviral therapy for prevention of horizontal HBV transmission in high-risk groups, (2) antiviral therapy versus observation for persons in the immune-tolerant phase, (3) discontinuation versus continuation of nucleos(t)ide analogue therapy in HBeAg-negative individuals with undetectable HBV DNA, and (4) hepatocellular carcinoma (HCC) surveillance in non-cirrhotic individuals with HBsAg clearance or co-infections with HCV, HDV, or HIV. RESULTS: For PICO 1, limited evidence suggests antiviral therapy may reduce horizontal transmission risk, though with low certainty. PICO 2 analyses reveal uncertain benefits of treating persons in the immune-tolerant phase, with very low certainty due to heterogeneity and bias. PICO 3 analyses demonstrate that discontinuing antiviral therapy in persons who are HBeAg negative with undetectable HBV DNA increases HBsAg loss rates (OR: 12.65, 95% CI: 1.58-101.51) but carries moderate risks of virologic relapse (OR: 47.17, 95% CI: 2.79-797.35) and clinical flares. PICO 4 analyses on several cohort studies showed that in patients co-infected with HCV, HBV, or HIV, the annual incidence of HCC was higher than the level where screening becomes cost-effective, suggesting that regular liver cancer screening could be beneficial for these patients. CONCLUSIONS: Despite low certainty, the findings support shared decision-making in high-risk horizontal transmission scenarios or in treating individuals in the immune tolerance phase, caution in discontinuing antiviral therapy in virologically suppressed individuals without HBsAg loss, and tailored HCC surveillance for those with co-infection or cirrhosis.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Pan CQ, Saadi S, Ghany MG, et al. Technical systematic review supporting the 2025 AASLD Practice Guideline on management of chronic hepatitis B. Hepatology. 2025. PMID: 41186417. doi:10.1097/HEP.0000000000001584

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。